Inclusion Criteria:

- Men or women of at least 18 years of age

- Histologically proven Bladder cancer

- Locally advanced or metastatic disease (stage IV)

- Functional status (ECOG / OMS) ≤ 2

- Relapse after first-line chemotherapy

- Measurable lesions (RECIST criteria)

- Absence of anti-neoplasic treatment in the 4 weeks preceding inclusion.

- Biological levels :

- Neutrophil count >1,5.109/L.

- Platelets >100.109/L

- Total serum bilirubin < 1.5 × ULN

- Clearance of créatinine 40 ml/mm

- If not liver metastasis alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) <2.5 × ULN

- With liver alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <5 ×
ULN

- Signed informed consent France only : Patients affiliated to a social security
program

Exclusion Criteria:

- Presence of uncontrolled metastatic brain or meningeal tumours

- Chemotherapy, immunotherapy, or radiotherapy within 4 weeks of inclusion

- Known hypersensitivity to temsirolimus, or its metabolites (as sirolimus), or
polysorbate 80 or to their excipients

- Previous malignancy (except for cervical carcinoma in situ, basal cell carcinoma
curatively treated) or incidental (≤ pT2) prostate cancer found on a radical
cystoprostatectomy material

- Auto-immune pathology, psychiatric or neurological disorder

- Any unstable medical condition

- Unstable cardiac disease

- Severe renal failure

- Unstable diabetes

- Pregnancy

- Patient enrolled in another therapeutic clinical trial

- Patient unable to follow and comply with the study procedures because of any
geographical, social or medical condition

- Patient partially or totally deprived of his civil rights